Maximizing MRI technology

Attendees at this year’s American Society of Neuroimaging annual meeting will have their first opportunity to see and hear how quantitative MRI (qMRI) and quantitative susceptibility mapping (QSM) tools are now practical for – and being used in — everyday clinical practice. QSM is just one of the advanced outputs available with STAGE and is… “ASN 2023: The Arrival of Practical QSM Tools Enhanced for Everyday Clinical Practice”

A new report from UPMC’s Center for Connected Medicine and KLAS Research about the AI use cases that health systems are prioritizing over the next few years includes findings about plans for radiology AI that raise two important questions for neuroradiologists and healthcare leaders: Based on a survey of 58 executives and senior managers at… “Health system priorities for AI and two important questions for radiology leaders”

Radiologists, neurologists, Alzheimer’s patients and their families are rightfully encouraged by the range of new drugs in development to slow or reduce cognitive decline. At the start of 2023 there were 187 trials for 141 drugs addressing Alzheimer’s pathologies. Two drugs, aducanumab and lecanemab, have received accelerated FDA approval in the past two years. A… “STAGE and the Promise and Challenges of New Alzheimer’s Drug Therapies”